Purchase this article with an account.
P.–C. Wu, H.–K. Kuo; Accommodation and Pupil Size in Schoolchildren with Low Concentration of Atropine for Controlling Myopic Progression . Invest. Ophthalmol. Vis. Sci. 2006;47(13):3680.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
1% or 0.5% atropine effectively slows myopia progression, it is associated with adverse effects, including photophobia, blurred near vision and poor compliance. We investigate whether low concentration of atropine (0.05%) could inhibit accommodation and reduce the severity of mydriasis.
Schoolchildren, from 7 to 14 years of age, treated each night with 0.05%, 0.1% atropine or none were included in this study. Objective accommodations and pupil diameters were measured in the afternoon of the next day.
Objective accommodation amplitude in 0.05% atropine group and 0.1% atropine group both significantly inhibited in comparison with control group (p=0.0001). However, there was no statistically significant between 0.05% atropine and 0.1% atropine (p=0.554). Pupil diameter in 0.05% atropine group and 0.1% atropine group both significantly larger than control group (p<0.0001). In addition, 0.05% atropine group had significant smaller pupil diameter than 0.1% group (p=0.0364)
0.05% atropine was found to be associated with inhibition in objective accommodation, with a concomitant less mydriasis than 0.1% atropine. It would be an alternative in treating myopia progression with poor compliance due to intolerance of photophobia.
This PDF is available to Subscribers Only